Background Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy
for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness …

Hepatocellular carcinoma (HCC) represents the most common primary liver cancer and is
considered a major global health problem as one of the leading causes of cancer-related …

Background/Aims Atezolizumab plus bevacizumab (ATE+ BEV) therapy has become the
recommended first-line therapy for patients with unresectable hepatocellular carcinoma …

Hepatocellular carcinoma (HCC) is one of the most common cancers and the third leading
cause of death worldwide. surgery, transarterial chemoembolization (TACE), systemic …

Background Atezolizumab-bevacizumab (atezo/bev) combination is a recommended first-
line systemic therapy for unresectable hepatocellular carcinoma (uHCC). There are no …

Background Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment
for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the …

Hepatocellular carcinoma (HCC) is the fourth most frequent cause of cancer-related death
worldwide. HCC frequently presents as advanced disease at diagnosis, and disease …

Background/Aim: The combination of atezolizumab plus bevacizumab (Atz/Bev) has become
widely used as a first-line therapy for advanced hepatocellular carcinoma (HCC). However …

Background Atezolizumab plus bevacizumab and lenvatinib are the current first-line
systematic therapy for unresectable hepatocellular carcinoma (uHCC). However, the …

Simple Summary Decompensated patients with hepatocellular carcinoma (HCC) are a wide
patient category with limited therapeutic options, and are often excluded from existing trials …